Calidi Biotherapeutics (CLDI) Competitors $0.73 -0.04 (-5.43%) Closing price 04:00 PM EasternExtended Trading$0.64 -0.10 (-13.01%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLDI vs. VXRT, XBIT, OCX, VIRI, CNTB, MIST, BYSI, IPA, ZURA, and ORMPShould you be buying Calidi Biotherapeutics stock or one of its competitors? The main competitors of Calidi Biotherapeutics include Vaxart (VXRT), XBiotech (XBIT), OncoCyte (OCX), Virios Therapeutics (VIRI), Connect Biopharma (CNTB), Milestone Pharmaceuticals (MIST), BeyondSpring (BYSI), ImmunoPrecise Antibodies (IPA), Zura Bio (ZURA), and Oramed Pharmaceuticals (ORMP). These companies are all part of the "pharmaceutical products" industry. Calidi Biotherapeutics vs. Its Competitors Vaxart XBiotech OncoCyte Virios Therapeutics Connect Biopharma Milestone Pharmaceuticals BeyondSpring ImmunoPrecise Antibodies Zura Bio Oramed Pharmaceuticals Vaxart (NASDAQ:VXRT) and Calidi Biotherapeutics (NYSE:CLDI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation. Do institutionals and insiders believe in VXRT or CLDI? 18.0% of Vaxart shares are owned by institutional investors. Comparatively, 12.5% of Calidi Biotherapeutics shares are owned by institutional investors. 2.9% of Vaxart shares are owned by insiders. Comparatively, 6.7% of Calidi Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer VXRT or CLDI? In the previous week, Calidi Biotherapeutics had 1 more articles in the media than Vaxart. MarketBeat recorded 3 mentions for Calidi Biotherapeutics and 2 mentions for Vaxart. Vaxart's average media sentiment score of 0.58 beat Calidi Biotherapeutics' score of 0.13 indicating that Vaxart is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxart 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Calidi Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is VXRT or CLDI more profitable? Calidi Biotherapeutics has a net margin of 0.00% compared to Vaxart's net margin of -122.63%. Calidi Biotherapeutics' return on equity of 0.00% beat Vaxart's return on equity.Company Net Margins Return on Equity Return on Assets Vaxart-122.63% -91.89% -38.40% Calidi Biotherapeutics N/A N/A -344.45% Which has preferable valuation and earnings, VXRT or CLDI? Calidi Biotherapeutics has lower revenue, but higher earnings than Vaxart. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxart$47.40M1.93-$66.95M-$0.27-1.48Calidi BiotherapeuticsN/AN/A-$29.22MN/AN/A Which has more volatility and risk, VXRT or CLDI? Vaxart has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, Calidi Biotherapeutics has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Do analysts recommend VXRT or CLDI? Vaxart presently has a consensus price target of $3.00, indicating a potential upside of 650.00%. Given Vaxart's stronger consensus rating and higher possible upside, research analysts plainly believe Vaxart is more favorable than Calidi Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxart 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Calidi Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryVaxart beats Calidi Biotherapeutics on 8 of the 13 factors compared between the two stocks. Get Calidi Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLDI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLDI vs. The Competition Export to ExcelMetricCalidi BiotherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$28.04M$272.87M$5.74B$21.13BDividend YieldN/AN/A4.60%3.58%P/E RatioN/AN/A28.1127.87Price / SalesN/A364.38461.3759.63Price / CashN/A22.4436.5523.02Price / Book-0.3112.418.654.69Net Income-$29.22M-$106.40M$3.25B$995.51M7 Day Performance22.98%4.86%4.20%1.64%1 Month Performance217.94%25.43%10.82%5.92%1 Year Performance-57.11%11.08%34.70%11.50% Calidi Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLDICalidi Biotherapeutics0.5592 of 5 stars$0.73-5.4%N/A-53.8%$28.04MN/A0.0038Gap DownVXRTVaxart3.1579 of 5 stars$0.40+6.5%$3.00+655.1%-39.3%$90.95M$47.40M-1.47120News CoverageGap DownXBITXBiotech1.6343 of 5 stars$2.98+8.4%N/A-55.0%$90.85MN/A-2.31100Positive NewsOCXOncoCyte1.2348 of 5 stars$3.18+16.3%$6.06+90.9%-1.1%$90.80M$3.84M-0.90120VIRIVirios TherapeuticsN/A$4.70-7.5%$5.00+6.4%+1,990.2%$90.51MN/A-17.415CNTBConnect Biopharma2.8479 of 5 stars$1.62+11.0%$7.00+332.1%+74.1%$90.01M$26.03M0.00110Analyst UpgradeAnalyst RevisionHigh Trading VolumeMISTMilestone Pharmaceuticals2.8103 of 5 stars$1.67+12.8%$7.00+319.2%+6.1%$89.28M$1M-2.1430High Trading VolumeBYSIBeyondSpringN/A$2.21-4.3%N/A+2.1%$89.10MN/A0.0080Positive NewsIPAImmunoPrecise Antibodies3.028 of 5 stars$1.93+6.0%$4.00+107.3%+164.6%$88.32M$18.16M-1.6680News CoverageUpcoming EarningsGap UpZURAZura Bio3.1063 of 5 stars$1.29-0.8%$14.33+1,011.1%-54.6%$88.20MN/A-1.843ORMPOramed Pharmaceuticals1.1278 of 5 stars$2.11+1.0%N/A-13.2%$86.19M$2M-4.8010News CoveragePositive News Related Companies and Tools Related Companies Vaxart Competitors XBiotech Competitors OncoCyte Competitors Virios Therapeutics Competitors Connect Biopharma Competitors Milestone Pharmaceuticals Competitors BeyondSpring Competitors ImmunoPrecise Antibodies Competitors Zura Bio Competitors Oramed Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CLDI) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calidi Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calidi Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
